-
-
-
-
-
-
-
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
-
-
-
-
-
-
-
858 Therapeutics Expands Board of Directors and Leadership Team
-
-
-
-
-
-
-
Ultragenyx Pharma (RARE) Appoints Corsee Sanders to its Board
-
-
-
-
-
-
-
Amgen (AMGN) Commences Strategic Collaboration With BeiGene (BGNE) to Expand Oncology Presence in China
-
-
-
-
-
-
-
BeiGene (BGNE) Spend Increase Takes $30 Out of Piper's PT
-
-
-
-
-
-
-
Immuno-Oncology Sector Deals Dominate 2017 Life Sciences Deal of the Year Awards
-
-
-
-
-
-
-
BeiGene (BGNE), Celgene (CELG) Enter Global Strategic Immuno-Oncology Collaboration; BeiGene Paid $263M Upfront and Celgene to Acquire 5.9% Stake
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

